RXRX250110C8500
- 0.03
- -0.02-40.00%
Recursion Pharmaceuticals Newsroom
Recursion Pharmaceuticals Is Maintained at Overweight by Keybanc
Recursion Pharmaceuticals Analyst Ratings
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $10
KeyBanc Lowers Price Target on Recursion Pharmaceuticals to $10 From $12, Keeps Overweight Rating
Recursion Pharmaceuticals Announces 2 Key Investigational Oncology Drugs Advancing To Clinical Trials, Targeting High Unmet Needs In Hematologic Malignancies, Small-Cell Lung Cancer, & More
Express News | Recursion Pharmaceuticals Inc - First Patient to Be Dosed in Phase 1 Excelerize Trial in Q1 2025
Express News | Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $10
Express News | Recursion Pharmaceuticals Inc : BofA Global Research Cuts Price Objective to $10 From $12
The "magic of the profit-making effect" is frequently appearing! NVIDIA's latest investment blueprint has been released, and these 13 companies are expected to take off.
Apart from NVIDIA itself, the key tracks and companies it invests in and pays attention to are also frequently favored by the U.S. stock market. The market believes that NVIDIA's investments often represent the development direction of the Industry, reflect the key areas of AI technology applications, and hint at potential technological breakthroughs.
Cathie Wood's ARK Innovation ETF Couldn't Keep Up in 2024
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer
Cathie Wood's Ark Invest Books Profits On Hot AI Stock Palantir, Sells Bitcoin ETF Shares As BTC Starts 2025 On A Positive Note
Nio, Unity Software And Other Big Stocks Moving Higher On Thursday
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 30% Share Price Surge Not Quite Adding Up
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
Express News | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Express News | Recursion Pharmaceuticals Inc - Registering for Resale 3.5 Mln Shares of Class a Common Stock